Ponatinib clinical trials
Also written AP24534 and Iclusig.
How each study uses ponatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ponatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Dec 2012 · ICLUSIG · NDA 203469 (FDA, Drugs@FDA)
- European Union
- 1 Jul 2013 · Iclusig · EMEA/H/C/002695 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
52 studies that test it; most in 2013 (7)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 7 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 5 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 40
M.D. Anderson Cancer Center (9) · Ariad Pharmaceuticals (6) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · Takeda (3) · Versailles Hospital (3) · Dana-Farber Cancer Institute (2) · Centre Leon Berard (1) · Otsuka Beijing Research Institute (1)
Often tested with
Tested in the same studies.
Blinatumomab (5) · Cytarabine (3) · Venetoclax (3) · Dasatinib (3) · Imatinib (2) · Azacitidine (2) · Methotrexate (2) · Decitabine (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test ponatinib, phase 3 first.
- Sep 2027Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLPhase 3 · Gruppo Italiano Malattie EMatologiche dell'Adulto
- Feb 2027Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaPhase 2 · M.D. Anderson Cancer Center
- Oct 2027Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaPhase 2 · M.D. Anderson Cancer Center
- Nov 2027Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaPhase 2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses ponatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 52
- Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsRecruitingPhase 1/2Incyte Biosciences International SàrlNCT03934372Written as PonatinibHow we know
- Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03263572Written as PonatinibHow we know
- Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibRecruitingPhase 2M.D. Anderson Cancer CenterNCT01746836Written as Ponatinib HydrochlorideHow we know
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/LymphomaRecruitingPhase 2University of WashingtonNCT07224100Written as PonatinibHow we know
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079Written as PonatinibHow we know
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)RecruitingPhase 2University of ChicagoNCT04747912Written as PonatinibHow we know
- Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCTRecruitingPhase 2Goethe UniversityNCT06061094Written as PonatinibHow we know
- Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid LeukemiaNot yet recruitingPhase 2Associazione Italiana Pazienti Leucemia Mieloide CronicaNCT04709731Written as Ponatinib 15mg QDHow we know
- Study in Adult Ph-positive ALLNot yet recruitingPhase 2Cardiff UniversityNCT04688983Written as PonatinibHow we know
- The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I MutationCompletedPhase 2Otsuka Beijing Research InstituteNCT04233346Written as Ponatinib 30mg ODHow we know
- Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)CompletedPhase 2Fundacion CRIS de Investigación para Vencer el CáncerNCT04160546Written as Ponatinib 15 MGHow we know
- Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT01424982Written as PonatinibHow we know
- Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03147612Written as PonatinibHow we know
- Ponatinib for FLT3-ITD Acute Myelogenous LeukemiaCompletedPhase 1/2Versailles HospitalNCT02428543Written as Ponatinib and CytarabineHow we know
- PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISISCompletedPhase 2Versailles HospitalNCT03895671Written as PonatinibHow we know
- Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedPhase 2M.D. Anderson Cancer CenterNCT04188405Written as PonatinibHow we know
- A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaTerminatedPhase 2M.D. Anderson Cancer CenterNCT05268003Written as PonatinibHow we know
- Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of DosesCompletedPhase 2TakedaNCT02467270Written as PonatinibHow we know
- Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia PatientsActive, not recruitingPhase 2Gruppo Italiano Malattie EMatologiche dell'AdultoNCT05306301Written as PonatinibHow we know
- Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)TerminatedPhase 2M.D. Anderson Cancer CenterNCT01570868Written as PonatinibHow we know
See all 52 studies that test ponatinib →
Given beside what is tested · 7 — ponatinib is usual care or a partner of the new treatment
- Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT03739814Written as PonatinibHow we know
- A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)RecruitingPhase 1/2University of ChicagoNCT06207123Written as PonatinibHow we know
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsActive, not recruitingPhase 3National Cancer Institute (NCI)NCT04530565Written as Ponatinib HydrochlorideHow we know
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as PonatinibHow we know
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431Written as PonatinibHow we know
- Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic LeukemiaStatus unknownPhase 2PETHEMA FoundationNCT02776605Written as PonatinibHow we know
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedPhase 1OHSU Knight Cancer InstituteNCT02779283Written as Ponatinib HydrochlorideHow we know
Codes
What other systems call ponatinib · ClinicalTrials.gg INT005531
- MeSH (NLM) C545373ponatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4340891KFSPONATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1364347Confirmed FDA, Wikidata
- Wikidata Q198728ponatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95777PonatinibOne source FDA
- DrugBank DB08901One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545373 | ponatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4340891KFS | PONATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1364347 | — | Confirmed FDA, Wikidata |
| Wikidata | Q198728 | ponatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95777 | Ponatinib | One source FDA |
| DrugBank | DB08901 | — | One source Wikidata |
Also registered as ponatinib hydrochloride (UNII 96R6PU3D8J · RxNorm 1364953).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.